<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275521</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2010/39</org_study_id>
    <nct_id>NCT01275521</nct_id>
  </id_info>
  <brief_title>A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy</brief_title>
  <acronym>PROTOX</acronym>
  <official_title>Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BPH is very common in elderly men, it is a stromal as well as epithelial invasion of the
      prostatic gland. Due to an imbalance between growth and apoptosis cellular mechanisms that
      are not fully elucidated. It is the same for symptomatology and urodynamic obstruction
      without clear identification of the part which is due to static phenomena (volume increase)
      and dynamic reports (α 1-receptor action). That explains the multiplicity of treatments and
      the difficulty of therapeutic indications between monitoring, medical treatment, and surgical
      operation. Experimental studies of BONT-A intra prostatic injection on animal and human
      models, have shown efficacy in BPH cell apoptosis, decrease in cell growth and decline in the
      number of adrenergic α1 receptors.

      Many studies in humans show therapeutic efficacy leading to a possible use of BONT-A as mini
      invasive treatment of symptomatic BPH, as an alternative to medical or surgical treatment.

      PROTOX study proposes to evaluate tolerance and effectiveness of the intra-prostatique BONT-A
      injection in the treatment of symptomatic BPH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2011</start_date>
  <completion_date type="Actual">April 28, 2015</completion_date>
  <primary_completion_date type="Actual">April 28, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the patient with auto-questionnaire IPSS urinary symptomatology: questions 1 to 7 (0 to 35 score).</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IPSS question 8 (score 0 to 6)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uroflowmetry (Qmax in ml/s)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• measure the post-voiding residue assessed by supra pubic ultrasound or urinary drainage</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of prostate volume assessed by endo-rectal ultrasound</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of the erectile function by auto questionnaire IIEF-5 (0 to 24 score)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary continence Evaluation by ICS 1 (0 to 23 score) and ICS 2 (0 to 12 score)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bladder emptying mode (spontaneous or permanent probe)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>specific treatment for BPH (alpha blocking, 5 alpha reductase inhibitor and/or phytotherapy)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary retention</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>profile of gene and protein expression on the first urine flow after prostate massage</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>BONT-A intra-prostatic injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>optimized medical BPH treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BONT-A intra-prostatic injection</intervention_name>
    <description>• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.
Interruption of the medical therapy 1 month after the injection;</description>
    <arm_group_label>BONT-A intra-prostatic injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized medical BPH treatment</intervention_name>
    <description>Optimization of the medical therapy according to recent guidelines</description>
    <arm_group_label>optimized medical BPH treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 50 to 85;

          -  Obstructive or irritative urinary symptomatology linked to a BPH;

          -  Score IPSS moderate to severe (8-19: moderate; 20-35: severe) or IPSS ≤ 7 in patient
             medically treated for symptomatic BPH;

          -  Increase in prostate volume on the rectal touch or ultrasound;

          -  Free consent, informed and written, dated and signed by the patient and the
             investigator (at the latest the day inclusion and before any examination requires the
             study);

          -  Subject affiliate or beneficiary of a social protection

        Exclusion Criteria:

          -  stenosis of the urethra confirmed by endoscopic or radiological examination;

          -  prostate cancer suspicion;

          -  medical past history of surgery, radiotherapy or pelvic trauma (, breach of the
             urethra, pubic symphysis disjunction);

          -  surgical resection of the prostate (adenomecty);

          -  clinical or paraclinical signs of vesical sphincterial disynergia; chronic urinary
             retention &gt; 500 ml;

          -  BPH complications making surgery necessary: effects on the upper urinary tract:
             dilatation or renal obstructive insufficiency, bladder stones or diverticula.

          -  patient previously treated by botulic toxin (whatever injection site);

          -  Persons unable to understand the course of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grégoire ROBERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine BENARD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Urologie - CH du Pays d'Aix - Avenue de Tamaris</name>
      <address>
        <city>AIX-en-PROVENCE</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie, CHU d'Angers 4, rue Larrey</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'urologie, Groupe Hospitalier Pellegrin, place Amélie Raba Léon</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'urologie - APHP Henri Mondor - 51, avenue du Maréchal de Lattre de Tassigny</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'urologie - CHU de Limoges - 2, avenue Martin Luther King</name>
      <address>
        <city>Limoges</city>
        <zip>87052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'urologie - Hôpital de la Conception - 147 boulevard Baille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste Beausoleil</name>
      <address>
        <city>Montpellier</city>
        <zip>33070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie - APHP Hopital Cochin - 27, Rue du faubourg Saint Jacques</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie - APHP Hôpital Saint Louis - 1, avenue Claude-vellefaux</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie - Hospices Civls de Lyon - 165 chemin du grand Revoyet</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'urologie - CHRU Strasbourg - BP 426</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Costa P, Ben Naoum K, Boukaram M, Wagner L, Louis JF. [Benign prostatic hyperplasia (BPH): prevalence in general practice and practical approach of French general practitioners. Results of a study based on 17,953 patients]. Prog Urol. 2004 Feb;14(1):33-9. French.</citation>
    <PMID>15098749</PMID>
  </reference>
  <reference>
    <citation>Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology. 1999 Jun;53(6):1090-8. Review.</citation>
    <PMID>10367833</PMID>
  </reference>
  <reference>
    <citation>Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989;2:33-50. Review.</citation>
    <PMID>2482772</PMID>
  </reference>
  <reference>
    <citation>Chute CG, Stephenson WP, Guess HA, Lieber M. Benign prostatic hyperplasia: a population-based study. Eur Urol. 1991;20 Suppl 1:11-7.</citation>
    <PMID>1722154</PMID>
  </reference>
  <reference>
    <citation>McConnell JD. The pathophysiology of benign prostatic hyperplasia. J Androl. 1991 Nov-Dec;12(6):356-63. Review.</citation>
    <PMID>1722791</PMID>
  </reference>
  <reference>
    <citation>Barrack ER, Bujnovszky P, Walsh PC. Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res. 1983 Mar;43(3):1107-16.</citation>
    <PMID>6186370</PMID>
  </reference>
  <reference>
    <citation>Marcelli M, Shao TC, Li X, Yin H, Marani M, Denner L, Teng B, Cunningham GR. Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7. J Urol. 2000 Aug;164(2):518-25.</citation>
    <PMID>10893637</PMID>
  </reference>
  <reference>
    <citation>Colombel M, Vacherot F, Diez SG, Fontaine E, Buttyan R, Chopin D. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia. Br J Urol. 1998 Sep;82(3):380-5.</citation>
    <PMID>9772874</PMID>
  </reference>
  <reference>
    <citation>Radlmaier A, Eickenberg HU, Fletcher MS, Fourcade RO, Reis Santos JM, van Aubel OG, Bono AV. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate. 1996 Oct;29(4):199-208.</citation>
    <PMID>8876703</PMID>
  </reference>
  <reference>
    <citation>Frick J. [Pathophysiology of benign prostatic hyperplasia]. Wien Med Wochenschr. 1996;146(8):158-60. Review. German.</citation>
    <PMID>8767399</PMID>
  </reference>
  <reference>
    <citation>Hieble JP, Boyce AJ, Caine M. Comparison of the alpha-adrenoceptor characteristics in human and canine prostate. Fed Proc. 1986 Oct;45(11):2609-14.</citation>
    <PMID>2428671</PMID>
  </reference>
  <reference>
    <citation>Hieble JP, Ruffolo RR Jr. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res. 1996 Mar;33(3):145-60. Review.</citation>
    <PMID>8880886</PMID>
  </reference>
  <reference>
    <citation>Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004 Nov;46(5):547-54.</citation>
    <PMID>15474261</PMID>
  </reference>
  <reference>
    <citation>Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr. 2000 Dec;3(4A):459-72.</citation>
    <PMID>11276294</PMID>
  </reference>
  <reference>
    <citation>Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998 Nov 11;280(18):1604-9. Erratum in: JAMA 1999 Feb 10;281(6):515.</citation>
    <PMID>9820264</PMID>
  </reference>
  <reference>
    <citation>Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009 Feb;1155:43-56. doi: 10.1111/j.1749-6632.2009.04115.x. Review.</citation>
    <PMID>19250191</PMID>
  </reference>
  <reference>
    <citation>Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG; MTOPS RESEARCH Group. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006 Apr;175(4):1422-6; discussion 1426-7.</citation>
    <PMID>16516013</PMID>
  </reference>
  <reference>
    <citation>Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996 Sep;48(3):398-405.</citation>
    <PMID>8804493</PMID>
  </reference>
  <reference>
    <citation>Desgrandchamps F. [Combination therapy in benign prostatic hyperplasia (BPH)]. Ann Urol (Paris). 2004 Dec;38 Suppl 2:S24-8. Review. French.</citation>
    <PMID>15651487</PMID>
  </reference>
  <reference>
    <citation>Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999 Oct;162(4):1301-6.</citation>
    <PMID>10492184</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

